SLC2A5 and breast cancer: Compared to estrogen receptor–positive breast cancer, triple-negative breast cancer cells and tissues express significantly higher levels of both GLUT5 protein and mRNA (as analyzed from breast cancer patient samples), making it an intriguing target for diagnosis and therapeutic application [22].